DelveInsight’s “POMC Deficiency Obesity Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the POMC Deficiency Obesity, historical and forecasted epidemiology as well as the POMC Deficiency Obesity market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the POMC Deficiency Obesity market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; POMC Deficiency Obesity Market Forecast

Some of the key facts of the POMC Deficiency Obesity Market Report:

• The POMC Deficiency Obesity market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In March 2025, Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharma company dedicated to improving the lives of people with rare neuroendocrine disorders, has announced the presentation of new real-world data at two European conferences. The data highlight consistent improvements in body mass index (BMI), BMI-z, and hunger scores among 35 patients with either acquired or congenital hypothalamic obesity who were treated with setmelanotide for up to nine months.

• In March 2025, Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company dedicated to improving the lives of patients with rare neuroendocrine disorders, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to setmelanotide for the treatment of acquired hypothalamic obesity.

• In December 2024, Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company dedicated to improving the lives of people with rare neuroendocrine diseases, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded use for IMCIVREE® (setmelanotide). The approval now includes children as young as 2 years old, allowing IMCIVREE to be used for reducing excess body weight and maintaining long-term weight loss in patients aged 2 and older with syndromic or monogenic obesity caused by Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC) deficiency, including PCSK1 or leptin receptor (LEPR) deficiencies.

• In 2023, the United States held the largest market share for POMC Deficiency Obesity, exceeding USD 2,000 million. This surpassed the market sizes of POMC Deficiency Obesity in comparison to the European Union Four (EU4) countries (Germany, Spain, Italy, France), the United Kingdom, and Japan.

• In 2023, the United States held the largest POMC Deficiency Obesity market share, exceeding USD 2,000 million, surpassing the EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

• By the year 2034, it is expected that WEGOVY (Semaglutide) and ZEPBOUND (Tirzepatide) will attain significant market dominance across the seven major markets.

• In recent times, there has been an increasing emphasis on the creation of innovative treatments for POMC Deficiency Obesity, which encompass drug combinations like SAXENDA (Liraglutide), XENICAL (Orlistat), WEGOVY (Semaglutide), QYSMIA (Phentermine-Topiramate), among others.

• DelveInsight’s estimates suggest that approximately 60% of the total prevalent cases of POMC Deficiency Obesity among adults in the 7 major markets (7MM) were accounted for by the United States in 2023.

• Key POMC Deficiency Obesity Companies: Rhythm Pharmaceuticals, Boehringer Ingelhium, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, and others

• Key POMC Deficiency Obesity Therapies: IMCIVREE (setmelanotide), ZEPBOUND (tirzepatide), Semaglutide oral, Survodutide (BI 456906), DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Semaglutide, and others

• The POMC Deficiency Obesity market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage POMC Deficiency Obesity pipeline products will significantly revolutionize the POMC Deficiency Obesity market dynamics.

POMC Deficiency Obesity Overview

POMC Deficiency Obesity is a medical condition characterized by excessive body fat accumulation, which can negatively impact health. It is typically measured using the Body Mass Index (BMI), with a BMI of 30 or higher indicating POMC Deficiency Obesity. This condition increases the risk of various health issues, including heart disease, diabetes, hypertension, and certain cancers. POMC Deficiency Obesity can result from multiple factors, such as poor diet, lack of physical activity, genetics, and hormonal imbalances. Effective management includes lifestyle changes, medical treatments, and, in some cases, surgical interventions to improve overall health and reduce associated risks.

Get a Free sample for the POMC Deficiency Obesity Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/het-obesity-pomc-deficiency-obesity-market

POMC Deficiency Obesity Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

POMC Deficiency Obesity Epidemiology Segmentation:

The POMC Deficiency Obesity market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of POMC Deficiency Obesity

• Prevalent Cases of POMC Deficiency Obesity by severity

• Gender-specific Prevalence of POMC Deficiency Obesity

• Diagnosed Cases of Episodic and Chronic POMC Deficiency Obesity

Download the report to understand which factors are driving POMC Deficiency Obesity epidemiology trends @ POMC Deficiency Obesity Epidemiology Forecast

POMC Deficiency Obesity Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the POMC Deficiency Obesity market or expected to get launched during the study period. The analysis covers POMC Deficiency Obesity market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the POMC Deficiency Obesity Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Obesity Therapies and Key Companies

• IMCIVREE (setmelanotide): Rhythm Pharmaceuticals

• ZEPBOUND (tirzepatide): Eli Lilly and Company

• Survodutide (BI 456906): Boehringer Ingelhium

• DD03: D&D Pharmatech

• AX-0601: ProQR Therapeutics

• NPM 139: Nano Precision Medical

• BK-1701: Bukwang Pharmaceutical

• CBW-520: Caliway Biopharmaceutics

• YH34160: Yuhan

• TERN-601: Terns Pharmaceuticals

• Thermostem: BioRestorative Therapies

• SCO-267: SCOHIA PHARMA

• CT-181: Click Therapeutics

• HM15136: Hanmi Pharmaceuticals

• NNC0480-0389: Novo Nordisk

• EMP-16: Empros Pharma

• CT-868: Carmot Therapeutics

• Tirzepatide: Eli Lilly and Company

• Semaglutide Oral: Novo Nordisk

Discover more about therapies set to grab major POMC Deficiency Obesity market share @ POMC Deficiency Obesity Treatment Landscape

POMC Deficiency Obesity Market Drivers

• Rise in prevalence of POMC Deficiency Obesity, growing Research and Development Activities to develop novel therapies to treat POMC Deficiency Obesity, changing lifestyle patterns are some of the important factors that are fueling the POMC Deficiency Obesity Market.

POMC Deficiency Obesity Market Barriers

• However, challenges associated with the discovery of anti-POMC Deficiency Obesity drugs, economic burden associated with POMC Deficiency Obesity and other factors are creating obstacles in the POMC Deficiency Obesity Market growth.

Scope of the POMC Deficiency Obesity Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key POMC Deficiency Obesity Companies: Rhythm Pharmaceuticals, Boehringer Ingelhium, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, and others

• Key POMC Deficiency Obesity Therapies: IMCIVREE (setmelanotide), ZEPBOUND (tirzepatide), Semaglutide oral, Survodutide (BI 456906), DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Semaglutide, and others

• POMC Deficiency Obesity Therapeutic Assessment: POMC Deficiency Obesity current marketed and POMC Deficiency Obesity emerging therapies

• POMC Deficiency Obesity Market Dynamics: POMC Deficiency Obesity market drivers and POMC Deficiency Obesity market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• POMC Deficiency Obesity Unmet Needs, KOL’s views, Analyst’s views, POMC Deficiency Obesity Market Access and Reimbursement

To know more about POMC Deficiency Obesity companies working in the treatment market, visit @ POMC Deficiency Obesity Clinical Trials and Therapeutic Assessment

Table of Contents

1. POMC Deficiency Obesity Market Report Introduction

2. Executive Summary for POMC Deficiency Obesity

3. SWOT analysis of POMC Deficiency Obesity

4. POMC Deficiency Obesity Patient Share (%) Overview at a Glance

5. POMC Deficiency Obesity Market Overview at a Glance

6. POMC Deficiency Obesity Disease Background and Overview

7. POMC Deficiency Obesity Epidemiology and Patient Population

8. Country-Specific Patient Population of POMC Deficiency Obesity

9. POMC Deficiency Obesity Current Treatment and Medical Practices

10. POMC Deficiency Obesity Unmet Needs

11. POMC Deficiency Obesity Emerging Therapies

12. POMC Deficiency Obesity Market Outlook

13. Country-Wise POMC Deficiency Obesity Market Analysis (2020–2034)

14. POMC Deficiency Obesity Market Access and Reimbursement of Therapies

15. POMC Deficiency Obesity Market Drivers

16. POMC Deficiency Obesity Market Barriers

17. POMC Deficiency Obesity Appendix

18. POMC Deficiency Obesity Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/